The AKAP12 antibody is a crucial tool for studying the A-kinase anchor protein 12 (AKAP12), a scaffold protein involved in organizing signaling complexes within cells. AKAP12. also known as gravin or SSeCKS, regulates key signaling pathways by tethering protein kinases (e.g., PKA, PKC) and phosphatases to specific subcellular locations. It plays roles in cell cycle progression, cytoskeletal organization, and cell adhesion, with emerging links to cancer suppression, metastasis inhibition, and vascular homeostasis.
Researchers use AKAP12 antibodies to detect protein expression, localization, and post-translational modifications (e.g., phosphorylation) in tissues or cultured cells. These antibodies are vital in cancer studies, as AKAP12 downregulation is associated with tumor progression in cancers like breast, prostate, and gastric cancer. Its tumor-suppressive functions involve inhibiting angiogenesis, epithelial-mesenchymal transition (EMT), and oncogenic signaling (e.g., Wnt/β-catenin).
Validated in techniques such as Western blotting, immunohistochemistry, and immunofluorescence, AKAP12 antibodies help elucidate its dynamic roles in cellular stress responses and drug resistance. Recent studies also explore AKAP12's involvement in neurological disorders and fibrosis. Specificity validation (e.g., knockout controls) is essential due to isoform diversity and tissue-specific expression patterns. This antibody remains a key reagent for dissecting AKAP12's multifaceted roles in physiology and disease. (299 words)